Crossroads in GDNF therapy for Parkinson's disease
Identifieur interne : 002861 ( Main/Exploration ); précédent : 002860; suivant : 002862Crossroads in GDNF therapy for Parkinson's disease
Auteurs : Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20861
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F17
- to stream Istex, to step Curation: 001F17
- to stream Istex, to step Checkpoint: 000C04
- to stream Main, to step Merge: 002B48
- to stream PascalFrancis, to step Corpus: 000854
- to stream PascalFrancis, to step Curation: 000469
- to stream PascalFrancis, to step Checkpoint: 000744
- to stream Main, to step Merge: 002C42
- to stream Main, to step Curation: 002861
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Crossroads in GDNF therapy for Parkinson's disease</title><author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B." last="Sherer">Todd B. Sherer</name></author><author><name sortKey="Fiske, Brian K" sort="Fiske, Brian K" uniqKey="Fiske B" first="Brian K." last="Fiske">Brian K. Fiske</name></author><author><name sortKey="Svendsen, Clive N" sort="Svendsen, Clive N" uniqKey="Svendsen C" first="Clive N." last="Svendsen">Clive N. Svendsen</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Langston, J William" sort="Langston, J William" uniqKey="Langston J" first="J. William" last="Langston">J. William Langston</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FBD375EF6A79165FA8441EB71DADF3B10B74AD80</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20861</idno><idno type="url">https://api-v5.istex.fr/document/FBD375EF6A79165FA8441EB71DADF3B10B74AD80/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F17</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F17</idno><idno type="wicri:Area/Istex/Curation">001F17</idno><idno type="wicri:Area/Istex/Checkpoint">000C04</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C04</idno><idno type="wicri:doubleKey">0885-3185:2006:Sherer T:crossroads:in:gdnf</idno><idno type="wicri:Area/Main/Merge">002B48</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0171936</idno><idno type="wicri:Area/PascalFrancis/Corpus">000854</idno><idno type="wicri:Area/PascalFrancis/Curation">000469</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000744</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000744</idno><idno type="wicri:doubleKey">0885-3185:2006:Sherer T:crossroads:in:gdnf</idno><idno type="wicri:Area/Main/Merge">002C42</idno><idno type="wicri:Area/Main/Curation">002861</idno><idno type="wicri:Area/Main/Exploration">002861</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Crossroads in GDNF therapy for Parkinson's disease</title><author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B." last="Sherer">Todd B. Sherer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Fiske, Brian K" sort="Fiske, Brian K" uniqKey="Fiske B" first="Brian K." last="Fiske">Brian K. Fiske</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Svendsen, Clive N" sort="Svendsen, Clive N" uniqKey="Svendsen C" first="Clive N." last="Svendsen">Clive N. Svendsen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Waisman Center, University of Wisconsin, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Langston, J William" sort="Langston, J William" uniqKey="Langston J" first="J. William" last="Langston">J. William Langston</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-02">2006-02</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="136">136</biblScope><biblScope unit="page" to="141">141</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FBD375EF6A79165FA8441EB71DADF3B10B74AD80</idno><idno type="DOI">10.1002/mds.20861</idno><idno type="ArticleID">MDS20861</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term><term>GDNF</term><term>Glial cell line derived neurotrophic factor</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Treatment</term><term>clinical trials</term><term>drug delivery</term><term>neuroimaging</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique</term><term>Facteur GDNF</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li><li>Wisconsin</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B." last="Sherer">Todd B. Sherer</name></region><name sortKey="Fiske, Brian K" sort="Fiske, Brian K" uniqKey="Fiske B" first="Brian K." last="Fiske">Brian K. Fiske</name><name sortKey="Langston, J William" sort="Langston, J William" uniqKey="Langston J" first="J. William" last="Langston">J. William Langston</name><name sortKey="Svendsen, Clive N" sort="Svendsen, Clive N" uniqKey="Svendsen C" first="Clive N." last="Svendsen">Clive N. Svendsen</name></country><country name="Canada"><noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002861 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002861 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FBD375EF6A79165FA8441EB71DADF3B10B74AD80
|texte= Crossroads in GDNF therapy for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |